Jones Lang LaSalle
Pharmos Corp.
(Nasdaq: PARS) has agreed to acquire Vela Pharmaceuticals Inc., a Ewing, N.J.–based drug company focused on CNS disorders. The deal is valued at approximately $29.7 million, including $5 million in cash and 11.5 million shares of Pharmos common stock. The deal also includes up to 8 million shares worth of milestone payments. Vela has raised around $58 million in total VC funding since its 1998 inception, from firms like Venrock Associates, New Enterprise Associates and JPMorgan Partners.
Pharmos Corp.
(Nasdaq: PARS) has agreed to acquire Vela Pharmaceuticals Inc., a Ewing, N.J.–based drug company focused on CNS disorders. The deal is valued at approximately $29.7 million, including $5 million in cash and 11.5 million shares of Pharmos common stock. The deal also includes up to 8 million shares worth of milestone payments. Vela has raised around $58 million in total VC funding since its 1998 inception, from firms like Venrock Associates, New Enterprise Associates and JPMorgan Partners.
posted by Jones Lang LaSalle NJ News Blog at 11:03 AM
<< Home